Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In brief

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Key facts

Study ID

NCT00090090

Run by

Spectrum Pharmaceuticals, Inc

People needed

114

Starts

2004-04-01

Expected to finish

2006-10-01

Last updated by the study team

2008-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
• at least one prior cytotoxic chemotherapy regimens
• measurable disease
• adequate bone marrow, liver and kidney function
• ECOG PS 0-2

You may not qualify if…

• prior treatment with elsamitrucin
• prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
• HIV positive or known AIDS syndrome
• uncontrolled medical disease or psychiatric condition/s

Where it is running

• Alta Bates Cancer Center — Berkeley, California, United States
• Providence Saint Joseph Medical Center — Burbank, California, United States
• USC Norris Cancer Center — Los Angeles, California, United States
• Tower Hematology Oncology Medical Group — Los Angeles, California, United States
• North Valley Hematology Oncology Medical Group — Mission Hills, California, United States
• Cancer and Blood Institute Medical Group — Rancho Mirage, California, United States
• North Shores University Hospital — Manhasset, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.